Indeed, even when captured with an EpCAM retrieval method, CTCs in breast and prostate cancer patients were found to co-express epithelial and mesenchymal markers in progressive disease [6], bringing up the question of how many EpCAM-negative mesenchymal cells were missed in the analysis. This evidence concerns the gene EPCAM and prostate carcinoma.